<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373295</url>
  </required_header>
  <id_info>
    <org_study_id>5232</org_study_id>
    <secondary_id>5P50DA009236</secondary_id>
    <nct_id>NCT00373295</nct_id>
  </id_info>
  <brief_title>Effect of Baclofen on Marijuana Withdrawal and Relapse</brief_title>
  <official_title>Effect of Baclofen on Marijuana Withdrawal and Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if baclofen dose-dependently decreases marijuana's
      direct effects and symptoms of marijuana withdrawal and thus decreases marijuana relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only a small percentage of dependent-marijuana smokers who are seeking treatment for their
      marijuana use are able to achieve sustained abstinence. The objective of this study is to
      investigate the interaction between marijuana and the potential treatment medication,
      baclofen, with the direct goal of using this information to improve marijuana treatment
      outcome. GABAB agonists such as baclofen have been shown to attenuate the self-administration
      of cocaine, heroin, alcohol and nicotine (see Cousins et al., 2002; Haney et al., 2006).
      Baclofen also appears to decrease withdrawal symptoms in heroin and alcohol abusers
      (Akhondzadeh et al., 2000; Addolorato et al., 2000). The purpose of this study is to
      determine if baclofen dose-dependently decreases marijuana's direct effects and symptoms of
      marijuana withdrawal and thus decreases marijuana relapse in our laboratory model. For the
      purposes of this model, relapse is defined as a return to marijuana use after a period of
      abstinence. The study will utilize an inpatient/outpatient, counter-balanced design, with
      each participant maintained on each of three medication conditions for 16 days: placebo and
      baclofen (60, 90 mg/day). Participants will begin taking capsules during the outpatient phase
      so that the dose can be incremented up to the maintenance dose prior to the first inpatient
      day. Further, clinical studies have shown that baclofen is most effective at decreasing
      cocaine's effects when administered for several weeks. During the inpatient study phases,
      participants will have the opportunity to self-administer placebo or active marijuana 6 times
      per day. This study will provide important information of the effect of baclofen as a
      potential treatment medication for marijuana dependence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of Relapse: Change in Money Spent Between Baseline and Relapse Phase</measure>
    <time_frame>Days 1-3 (Baseline) and Days 6-8 (Relapse Phase)</time_frame>
    <description>This is a measure of marijuana self-administration and relapse since each initial puff costs $7 and is a burden to overcome just to smoke.
Over each 3 day period, the puffs chosen by each participant is averaged for a single value.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Marijuana Dependence</condition>
  <arm_group>
    <arm_group_label>Baclofen 60 mg, Placebo, Baclofen 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baclofen 90 mg, Placebo, Baclofen 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baclofen 60 mg, Baclofen 90 mg, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baclofen 90 mg, Baclofen 60 mg, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Baclofen 90 mg, Baclofen 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Baclofen 60 mg, Baclofen 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <description>Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).</description>
    <arm_group_label>Baclofen 60 mg, Placebo, Baclofen 90 mg</arm_group_label>
    <arm_group_label>Baclofen 90 mg, Placebo, Baclofen 60 mg</arm_group_label>
    <arm_group_label>Baclofen 60 mg, Baclofen 90 mg, Placebo</arm_group_label>
    <arm_group_label>Baclofen 90 mg, Baclofen 60 mg, Placebo</arm_group_label>
    <arm_group_label>Placebo, Baclofen 90 mg, Baclofen 60 mg</arm_group_label>
    <arm_group_label>Placebo, Baclofen 60 mg, Baclofen 90 mg</arm_group_label>
    <other_name>Lioresal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marijuana</intervention_name>
    <description>Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.</description>
    <arm_group_label>Baclofen 60 mg, Placebo, Baclofen 90 mg</arm_group_label>
    <arm_group_label>Baclofen 90 mg, Placebo, Baclofen 60 mg</arm_group_label>
    <arm_group_label>Baclofen 60 mg, Baclofen 90 mg, Placebo</arm_group_label>
    <arm_group_label>Baclofen 90 mg, Baclofen 60 mg, Placebo</arm_group_label>
    <arm_group_label>Placebo, Baclofen 90 mg, Baclofen 60 mg</arm_group_label>
    <arm_group_label>Placebo, Baclofen 60 mg, Baclofen 90 mg</arm_group_label>
    <other_name>cannabis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Baclofen 60 mg, Placebo, Baclofen 90 mg</arm_group_label>
    <arm_group_label>Baclofen 90 mg, Placebo, Baclofen 60 mg</arm_group_label>
    <arm_group_label>Baclofen 60 mg, Baclofen 90 mg, Placebo</arm_group_label>
    <arm_group_label>Baclofen 90 mg, Baclofen 60 mg, Placebo</arm_group_label>
    <arm_group_label>Placebo, Baclofen 90 mg, Baclofen 60 mg</arm_group_label>
    <arm_group_label>Placebo, Baclofen 60 mg, Baclofen 90 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current marijuana use: average of 3 marijuana cigarettes at least 4 times per week for
             the past 4 weeks

          -  Able to perform study procedures

          -  21-45 years of age

          -  Women practicing an effective form of birth control (condoms, diaphragm, birth control
             pill, IUD)

        Exclusion Criteria:

          -  Current, repeated illicit drug use (other than marijuana)

          -  Presence of significant medical illness(e.g., diabetes, cardiovascular disease,
             hypertension, examination, laboratory clinically significant laboratory abnormalities)

          -  History of heart disease

          -  Request for drug treatment

          -  Current parole or probation

          -  Pregnancy or current lactation

          -  Recent history of significant violent behavior

          -  Major current Axis I psychopathology(e.g., major depressive disorder, bipolar
             disorder, suicide risk, schizophrenia)

          -  Current use of any prescription or over-the-counter medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Haney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Cooper ZD, Foltin RW. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl). 2010 Aug;211(2):233-44. doi: 10.1007/s00213-010-1888-6. Epub 2010 Jun 3.</citation>
    <PMID>20521030</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2006</study_first_submitted>
  <study_first_submitted_qc>September 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2006</study_first_posted>
  <results_first_submitted>October 20, 2016</results_first_submitted>
  <results_first_submitted_qc>March 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2017</results_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Baclofen</keyword>
  <keyword>Marijuana Dependence</keyword>
  <keyword>Marijuana Withdrawal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>13 participants were enrolled, but 10 participants were randomized. Three volunteers (1 female, 2 male) dropped out of the study during the marijuana abstinence phase (two were on baclofen and one was on placebo).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Baclofen 60 mg, Placebo, Baclofen 90 mg</title>
          <description>participants received baclofen (60 mg/day) for 8 days, followed by placebo for 8 days, then baclofen (90mg/day) for 8 days.</description>
        </group>
        <group group_id="P2">
          <title>Baclofen 90 mg, Placebo, Baclofen 60 mg</title>
          <description>participants received baclofen (90mg/day) for 8 days, followed by placebo for 8 days, then baclofen (60mg/day) for 8 days.</description>
        </group>
        <group group_id="P3">
          <title>Baclofen 60 mg, Baclofen 90 mg, Placebo</title>
          <description>participants received baclofen (60mg/day) for 8 days, followed by baclofen (90mg/day) for 8 days, then placebo for 8 days.</description>
        </group>
        <group group_id="P4">
          <title>Baclofen 90 mg, Baclofen 60 mg, Placebo</title>
          <description>participants received baclofen (90mg/day) for 8 days, followed by baclofen (60mg/day) for 8 days, and then placebo for 8 days.</description>
        </group>
        <group group_id="P5">
          <title>Placebo, Baclofen 90 mg, Baclofen 60 mg</title>
          <description>participants received placebo for 8 days, followed by baclofen (90mg/day) for 8 days, then baclofen (60mg/day) for 8 days.</description>
        </group>
        <group group_id="P6">
          <title>Placebo, Baclofen 60 mg, Baclofen 90 mg</title>
          <description>participants received placebo for 8 days, followed by baclofen (60mg/day) for 8 days, then baclofen (90mg/day) for 8 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1 (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Intervention 2 (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 3 (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants received placebo, baclofen (60mg) and baclofen (90mg) and smoked Marijuana (5.3% THC).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure of Relapse: Change in Money Spent Between Baseline and Relapse Phase</title>
        <description>This is a measure of marijuana self-administration and relapse since each initial puff costs $7 and is a burden to overcome just to smoke.
Over each 3 day period, the puffs chosen by each participant is averaged for a single value.</description>
        <time_frame>Days 1-3 (Baseline) and Days 6-8 (Relapse Phase)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baclofen 60, Marijuana</title>
            <description>baclofen (60 mg)/day
Baclofen: measured baclofen's effects on marijuana withdrawal and relapse relative to placebo
Marijuana: measured baclofen's effects on marijuana withdrawal and relapse</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Marijuana</title>
          </group>
          <group group_id="O3">
            <title>Baclofen 90, Marijuana</title>
            <description>baclofen (90 mg)/day
Baclofen: measured baclofen's effects on marijuana withdrawal and relapse relative to placebo
Marijuana: measured baclofen's effects on marijuana withdrawal and relapse</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Relapse: Change in Money Spent Between Baseline and Relapse Phase</title>
          <description>This is a measure of marijuana self-administration and relapse since each initial puff costs $7 and is a burden to overcome just to smoke.
Over each 3 day period, the puffs chosen by each participant is averaged for a single value.</description>
          <units>dollars spent on marijuana</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.15" spread="1.85"/>
                    <measurement group_id="O2" value="9.77" spread="2.30"/>
                    <measurement group_id="O3" value="7.25" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Baclofen 60, Marijuana</title>
          <description>baclofen (60 mg)/day
Baclofen: measured baclofen's effects on marijuana withdrawal and relapse relative to placebo
Marijuana: measured baclofen's effects on marijuana withdrawal and relapse</description>
        </group>
        <group group_id="E2">
          <title>Baclofen 90, Marijuana</title>
          <description>baclofen (90 mg)/day
Baclofen: measured baclofen's effects on marijuana withdrawal and relapse relative to placebo
Marijuana: measured baclofen's effects on marijuana withdrawal and relapse</description>
        </group>
        <group group_id="E3">
          <title>Placebo, Marijuana</title>
          <description>Marijuana: measured baclofen's effects on marijuana withdrawal and relapse</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>mild headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Margaret Haney</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-6129</phone>
      <email>reslabsurc@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

